Industry News
Amylyx to stop development of rare brain disorder drug after trial failure
Aug 27 (Reuters) - Amylyx Pharmaceuticals (AMLX.O) said on Wednesday it will stop development of its experimental drug for a rare brain disorder after it failed to improve symptoms in patients during a mid-stage trial.
Shares of the company fell 1.7% in premarket trading after the drug, AMX0035, showed no benefit over a placebo at 24 weeks in patients with a rare and fatal brain disorder called progressive supranuclear palsy (PSP).
Discover What's Happening
Business Sustainability Updates, Straight to Your Inbox
Explore our newsletters
Join our Newsletter to receive the latest industry trends, expert tips, and exclusive insights delivered straight to your inbox!
.png)
